The purpose of this study is to examine the effect that melatonin lotion has on sleep quality, the nervous system, and mental health. Melatonin is a hormone secreted by the brain that regulates sleep and might improve depression and anxiety symptoms. The goal is to determine whether melatonin in lotion form is an effective treatment for young adults with inadequate sleep and might improve mental health. Participants will fill out surveys, wear an actigraph (a wrist-worn device that measures sleep), wear a heart rate monitor (a strap worn around one's chest), and provide nightly saliva samples during treatment weeks. In one of the two treatment weeks, participants will receive a lotion that contains melatonin. During the other week they will receive a control treatment that will be lotion with no melatonin, and there will be a week in between with no treatment at all.
All participants will receive a melatonin lotion and a placebo lotion in a randomized crossover design. Participants will receive equipment and supplies on a Monday and will begin the assigned treatment that night, by self-applying premeasured lotion 1 hour before bedtime. During the two treatment weeks, participants will wear ActiGraph GT3X-BT accelerometers (ActiGraph, Pensacola, FL) at all times except when bathing or submerged in water. They will wear Polar H10 heart rate monitor chest straps (Polar Electro, Kempele, Finland) from one hour prior to bedtime until after a 5 min sitting period after waking. Three times daily they will be asked 1-item mood/anxiety questions ("How \_\_\_ do you feel right now?") through REDCap software. Participants will check any experienced side effects off a checklist once daily. Participants will collect a passive drool sample daily at bedtime and store in their home freezer until returning the samples to the laboratory. Treatment will occur for seven nights, with a return of equipment and saliva samples as well as confirmation of actigraphy and HRV readings the following Monday. After a seven day washout period to reduce any carryover effects, equipment and supplies will be supplied the next Monday and the participant will begin the other assigned treatment (active or placebo) that night in a crossover design. At three timepoints (pre-treatment, at the end of the melatonin treatment week, and at the end of the placebo week), participants will answer the following surveys online via REDCap: PROMIS short forms for anxiety, depression, sleep quality, and sleep-related impairment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
60
3 g lotion applied one hour before bedtime
3 g of placebo lotion (scent-matched control) applied one hour before bedtime
University of Redlands
Redlands, California, United States
RECRUITINGSleep disturbance
PROMIS SF v1.0 - Sleep Disturb 8b
Time frame: Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total)
Anxiety
PROMIS SF v1.0 - Anxiety 8a
Time frame: Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total)
Depression
PROMIS SF v1.0 - Depression 8b
Time frame: Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total)
Total sleep time
Measured via actigraphy
Time frame: Two weeks of data separated by a one week period
Sleep efficiency
Measured by actigraphy
Time frame: Two weeks of data separated by a one week period
Normalized high frequency power of heart rate variability
5 min period during sleep latency, overnight recording while sleeping, and 5 min period sitting upright each morning
Time frame: Two weeks of data separated by a one week period
Anxiety by momentary ecological assessment
One item question: "How anxious do you feel right now?"
Time frame: Three times per day for two weeks of data separated by a one week period
Mood by momentary ecological assessment
Single-item questions ("How \_\_\_ do you feel right now?)
Time frame: Three times per day for two weeks of data separated by a one week period
Salivary alpha-amylase
As an indicator of sympathetic nervous system activity
Time frame: Daily at bedtime for two weeks of data separated by a one week period
Sleep-related impairment
PROMIS SF v1.0 - Sleep-Related Impairment 8a
Time frame: Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total)
Other sleep variables
A MANOVA will be conducted with the primary sleep outcomes as well as sleep onset latency (both self-reported and as measured by actigraphy) and subjective sleep quality
Time frame: Two weeks of data separated by a one week period
Salivary melatonin
For confirmation of protocol compliance
Time frame: Daily at bedtime for two weeks of data separated by a one week period
Other HRV variables
A MANOVA will be conducted with autonomic nervous system indicators including normalized high frequency HRV and salivary alpha amylase as primary outcomes, but also including LF/HF ratio, RMSSD, and pNN50
Time frame: 5 min period sitting upright each morning after waking, and overnight data capture starting one hour before bedtime
Side effects
Frequency of headache, drowsiness, skin irritation, vivid dreams, nightmares, dizziness, and other
Time frame: Daily for two weeks of data separated by a one week period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.